

We claim:

1. A method for up-regulating tumor cell antigen expression comprising administering to the tumor cells an amount of thymalfasin sufficient to increase the expression of TLP relative to that of untreated tumor cells.
2. The method of claim 1, wherein the administration is to a patient in vivo.
3. The method of claim 2, wherein the thymalfasin is administered at a dose between 2 µg/kg body weight and 6 mg/kg body weight.
4. The method of claim 3, wherein the thymalfasin is administered at a dose between 20 µg/kg body weight and 200 µg/kg body weight.
5. A method for enhancing the sensitivity of a immunodiagnostic or immunotherapeutic method, comprising pre-treating target tumor cells by administering to the cells an amount of thymalfasin sufficient to increase the expression of TLP relative to that of untreated tumor cells, followed by application of the immunodiagnostic or immunotherapeutic method.
6. The method of claim 5, wherein the administration is to a patient in vivo.
7. The method of claim 6, wherein the thymalfasin is administered at a dose between 2 µg/kg body weight and 6 mg/kg body weight.

8. The method of claim 7, wherein the thymalfasin is administered at a dose between 20 µg/kg body weight and 200 µg/kg body weight.
9. The method of claim 1 wherein the administration is to cells in vitro.
10. The method of claim 5 wherein the administration is to cells in vitro.